Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study

American Journal of Gastroenterology

Volumn 112, Issue 11, 2017, Pages 1709-1718

  Ordas I ^a   Domenech E ^b   Manosa M ^b   Garcia Sanchez V ^c   Iglesias Flores, E ^c   Penalva M ^d   Canas Ventura A ^e   Merino, O ^f   Fernandez Banares F ^d   Gomollon F ^g   Vera, M ^h   Gutierrez A ⁱ   Garcia Planella, E ^j   Chaparro, M ^k   Aguas, M ^l   Gento, E ^m   Munoz F ⁿ   Aguirresarobe, M ^o   Munoz C ^p   Fernandez L ^q   Calvet, X ^a   Jimenez C E ^r   Montoro, M A ^s   Mir, A ^t   De Castro, M L ^u   Garcia Sepulcre M F ^v   Bermejo, F ^w   Panes J ^a   Esteve, M ^d   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Gastroenterology Department   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^l HOSPITAL UNIVERSITARIO LA FE   (Spain)

^m HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁿ Departamento de Cardiología   (Spain)

^o HOSPITAL DE GALDAKAO   (Spain)

^p HOSPITAL DE BASURTO   (Spain)

^q HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^r Universidad Pública de Navarra   (Spain)

^s HOSPITAL SAN JORGE   (Spain)

^t HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^u UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^v HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^w HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; SULFAMETHOXAZOLE; TRIMETHOPRIM; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE SEVERE ULCERATIVE COLITIS; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CHEMOPROPHYLAXIS; CHILD; COHORT ANALYSIS; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STEROID REFRACTORY ULCERATIVE COLITIS; STEROID THERAPY; ULCERATIVE COLITIS; ACUTE DISEASE; AGE; CHEMICALLY INDUCED; CLINICAL TRIAL; INFECTION; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INFLIXIMAB; MALE; MIDDLE AGED; MORTALITY; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85032989541     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.180     Document Type: Article

References (26)

1. Arts J, D'Haens G, Zeegers M et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Infl amm Bowel Dis 2004; 10: 73-8.
2. Jarnerot G, Hertervig E, Friis-Liby I et al. Infl iximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebocontrolled study. Gastroenterology 2005; 128: 1805-11.
3. Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infl iximab in patients with severe ulcerative colitis refractory to intravenous steroids: A parallel, open-label randomised controlled trial. Lancet 2012; 1: 1909-15.
4. Williams JG, Alam MF, Alrubaiy L et al. Comparison Of iNfl iximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technol Assess 2016; 20: 1-320.
5. Narula N, Marshall JK, Colombel JF et al. Systematic review and metaanalysis: infl iximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol 2016; 111: 477-91.
6. Laharie D, Bourreille A, Branche J et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infl iximab. Gut 2017; pii: gutjnl-2016-313060.
7. Edwards IR, Aronson JK. Adverse drug reactions: defi nitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
8. Gisbert JP, Barreiro-de Acosta M, Esteve M et al. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: Th e UC Horizons Project. Infl amm Bowel Dis 2016; 22: 583-98.
9. Van Assche G, Dignass A, Bokemeyer B et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33.
10. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
11. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
12. Actis GC, Volpes R, Rizzetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11: 905-8.
13. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infl iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
14. Domenech E, Garcia-Planella E, Bernal I et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-5.
15. Loft us CG, Loft us EV Jr., Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut 2003; 52: 172-3.
16. Sjoberg M, Walch A, Meshkat M et al. Infl iximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study. Infl amm Bowel Dis 2011; 18: 212-8.
17. Burger DC, Travis S. Colon salvage therapy for acute severe colitis: cyclosporine or infl iximab? Curr Opin Gastroenterol 2011; 27: 358-62.
18. Lichtenstein L, Ron Y, Kivity S et al. Infl iximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis 2015; 9: 806-15.
19. Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in infl iximab-and immunomodulatortreated adult patients with infl ammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-63.
20. Toruner M, Loft us EV Jr., Harmsen WS et al. Risk factors for opportunistic infections in patients with infl ammatory bowel disease. Gastroenterology 2008; 134: 929-36.
21. Fernandez-Banares F, Bertran X, Esteve-Comas M et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498-9.
22. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in infl ammatory bowel disease. J Crohns Colitis 2014; 8: 443-68.
23. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: A long-term experience. Eur J Gastroenterol Hepatol 2005; 17: 79-84.
24. Moskovitz DN, Van Assche G, Maenhout B et al. Incidence of colectomy during long-term follow-up aft er cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-5.
25. Sharkey L, Bredin F, Nightingale A et al. Th e use of Cyclosporin A in acute steroid-refractory ulcerative colitis: long term outcomes. J Crohns Colitis 2011; 5: 91-4.
26. Naves JE, Llao J, Ruiz-Cerulla A et al. Long-term comparative effi cacy of cyclosporine-or infl iximab-based strategies for the management of steroidrefractory ulcerative colitis attacks. Infl amm Bowel Dis 2014; 20: 1375-81.